Holen Sie sich die Stockscreener-App
3.15
0.32%
-0.01
Vorhandelsmarkt:
3.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.16
Offen:
$3.16
24-Stunden-Volumen:
7.26M
Relative Volume:
0.57
Marktkapitalisierung:
$811.73M
Einnahmen:
$418.24M
Nettoeinkommen (Verlust:
$-7.42M
KGV:
-30.46
EPS:
-0.1034
Netto-Cashflow:
$-10.88M
1W Leistung:
+0.00%
1M Leistung:
+0.64%
6M Leistung:
-15.32%
1J Leistung:
+169.23%
1-Tages-Spanne:
$3.15
$3.17
1-Wochen-Bereich:
$3.15
$3.17
52-Wochen-Spanne:
$1.10
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.15 | 814.31M | 418.24M | -7.42M | -10.88M | -0.1034 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
Esperion Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Esperion Therapeutics, Inc. Actuals & Estimates (NASDAQ:ESPR) - TradingView
ESPR Stock Price, Quote & Chart - ChartMill
Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET) - TradingView
ESPR Forecast — Price Target — Prediction for 2027 - TradingView
Esperion Therapeutics Inc (ESPR) Institutional Confidence - TradingKey
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades - Yahoo Finance
ESPR News | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion (NASDAQ: ESPR) CLO trims 11,824 shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M - Stock Titan
Esperion (NASDAQ: ESPR) CFO sells shares to pay taxes on vested RSUs - Stock Titan
Esperion (NASDAQ: ESPR) details Corstasis acquisition cost, debt and royalty financing - Stock Titan
Esperion Therapeutics (ESPR) Proxy filing Summary - Quartr
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inve - The National Law Review
ESPR insider sale notice: 53,588 shares tied to vesting (ESPR) - Stock Titan
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - Business Wire
Benjamin Halladay to sell 10,773 ESPR shares after vesting (ESPR) - Stock Titan
ESPR (NASDAQ: ESPR) files Form 144 to sell 11,824 vested shares - Stock Titan
Esperion Therapeutics Inc (ESPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Esperion Therapeutics Inc (ESPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Esperion Therapeutics Inc (ESPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Esperion Therapeutics Inc (ESPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Esperion Therapeutics Inc (ESPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Esperion Therapeutics Inc (ESPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Esperion (NASDAQ: ESPR) gains HSR clearance ahead merger vote - Stock Titan
Esperion Therapeutics Inc. (ESPR) News, Articles, Events & Latest Updates - Stocktwits
Esperion Gains German Approval for ArchiMed Acquisition Deal - TipRanks
German antitrust clears Esperion (ESPR) merger with ArchiMed affiliate Essence Parent - Stock Titan
Glazer Capital (ESPR) reports 20,975,620 shares, an 8.15% position - Stock Titan
New peer-reviewed paper by more than 20 protein experts calls for rethinking dietary protein guidance beyond "eat more protein": National Pork Board reports - EurekAlert!
Esperion Therapeutics (NASDAQ: ESPR) to be acquired for $3.16/share plus CVRs - Stock Titan
ESPR Stock Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics, Inc. 8-K Filing Details for May 28, 2026: Company Information, NASDAQ Listing, and Stock Option Plan Amendments - Minichart
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant - Stock Titan
Esperion Therapeutics (ESPR) director receives 79,873-share stock award - Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant - Stock Titan
Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant - Stock Titan
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award - Stock Titan
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Jun 17 '26 |
Sale |
3.15 |
53,588 |
169,070 |
2,119,111 |
| Halladay Benjamin | Chief Financial Officer |
Jun 17 '26 |
Sale |
3.15 |
10,773 |
33,989 |
702,829 |
1.03%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):